The Niche

NovoCell, Yamanaka make dream team against diabetes

One of the leading cell-therapy diabetes companies has just enlisted a rock star. The scientist who first described how to reprogram differentiated cells to pluripotency, Shinya Yamanaka of Kyoto University,has signed a deal with Novocell to use induced pluripotent stem (iPS) cells to replace the beta cells that are lost in diabetes. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE